Video wird geladen...

Video konnte nicht geladen werden

Beim Laden dieses Videos ist ein Problem aufgetreten. Dies könnte an einem vorübergehenden Netzwerkproblem liegen oder das Video ist möglicherweise nicht verfügbar.

The one shot longevity solution is around the corner. Crémieux casually mentioned on Health Care Network this week that there’s a PCSK9 + GLP-1 fusion drug already in development. Add a BP agent and you’ve knocked out ~90% of what actually kills people. What’s actually in the pipeline right... show more

Dr Danish

46,843 subscribers

17,667 Aufrufe • vor 10 Tagen •via X (Twitter)

Wissenschaft & Technologie Gesundheit & Wellness

Anya Rossi• Live Now

Private livecam show

0 Kommentare

Keine Kommentare verfügbar

Kommentare vom Original-Post werden hier angezeigt

Ähnliche Videos

Alex Karnal (Alex Karnal) is the most talented bio and healthcare investor I've ever met. He's spent 20 years in the industry and says 2025 was the single most exciting year he's seen. The start of a once-in-a-lifetime, trillion-dollar revolution in public health. He explains how few people realize we already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them. There's a population of people born with a mutation that means their bodies don't produce a protein called PCSK9. Their lifetime risk of cardiovascular disease is 88% lower than yours. Pharma turned that genetic advantage into a drug. It's been approved for years, but the number of people taking it is still vanishingly small. Partly because high cholesterol is a silent killer. You feel nothing, right up until you have a heart attack. And partly because the health system makes it punishingly hard to stay on a preventive drug like a PCSK9 inhibitor. In other words, the medicine works, but the system around it doesn't. That's what's starting to change, and in this episode, Alex explains why. We discuss the "health stack" he believes can add a decade to most lives, why oral GLP-1s are breaking every adoption record in pharma, peptides and citizen pharmacology, and what AI is doing to drug discovery. I wish I had an "Alex" for every interesting topic. We've been having versions of this conversation for over five years, and every single one is as clear and as useful as this one. Enjoy! Timestamps: 0:00 Intro 1:00 The State of Modern Medicine 5:00 Designing the Modern Health Stack 12:17 The GLP-1 Inflection Point 19:18 The Biological Mechanisms of GLP-1 30:36 Overcoming Frictions in Healthcare 34:19 Cardiovascular Disease 44:04 Addressing Alzheimer's 47:04 The Future of Cancer 57:33 Drug Discovery 1:05:25 AI and Scientific Super Intelligence 1:14:40 Citizen Pharmacology and the Peptide Movement 1:18:13 Background and Career Journey 1:31:09 Braidwell's Investment Approach 1:33:30 The Kindest Thing

Alex Karnal (Alex Karnal) is the most talented bio and healthcare investor I've ever met. He's spent 20 years in the industry and says 2025 was the single most exciting year he's seen. The start of a once-in-a-lifetime, trillion-dollar revolution in public health. He explains how few people realize we already have the medicines to prevent our deadliest diseases. The problem is that almost no one takes them. There's a population of people born with a mutation that means their bodies don't produce a protein called PCSK9. Their lifetime risk of cardiovascular disease is 88% lower than yours. Pharma turned that genetic advantage into a drug. It's been approved for years, but the number of people taking it is still vanishingly small. Partly because high cholesterol is a silent killer. You feel nothing, right up until you have a heart attack. And partly because the health system makes it punishingly hard to stay on a preventive drug like a PCSK9 inhibitor. In other words, the medicine works, but the system around it doesn't. That's what's starting to change, and in this episode, Alex explains why. We discuss the "health stack" he believes can add a decade to most lives, why oral GLP-1s are breaking every adoption record in pharma, peptides and citizen pharmacology, and what AI is doing to drug discovery. I wish I had an "Alex" for every interesting topic. We've been having versions of this conversation for over five years, and every single one is as clear and as useful as this one. Enjoy! Timestamps: 0:00 Intro 1:00 The State of Modern Medicine 5:00 Designing the Modern Health Stack 12:17 The GLP-1 Inflection Point 19:18 The Biological Mechanisms of GLP-1 30:36 Overcoming Frictions in Healthcare 34:19 Cardiovascular Disease 44:04 Addressing Alzheimer's 47:04 The Future of Cancer 57:33 Drug Discovery 1:05:25 AI and Scientific Super Intelligence 1:14:40 Citizen Pharmacology and the Peptide Movement 1:18:13 Background and Career Journey 1:31:09 Braidwell's Investment Approach 1:33:30 The Kindest Thing

Patrick OShaughnessy

678,402 Aufrufe • vor 4 Monaten

1 in 10 people globally interact with AI weekly. 1 IN 8 AMERICANS ARE ON A GLP-1. Finally, healthcare DEFLATION. While AI is reshaping how we do things, GLP-1s are reshaping human biology. And their convergence offers something the US healthcare system has never experienced in its entire history. As Eric Larsen points out, this is not a trend. This is a restructuring of humanity. eMed

1 in 10 people globally interact with AI weekly. 1 IN 8 AMERICANS ARE ON A GLP-1. Finally, healthcare DEFLATION. While AI is reshaping how we do things, GLP-1s are reshaping human biology. And their convergence offers something the US healthcare system has never experienced in its entire history. As Eric Larsen points out, this is not a trend. This is a restructuring of humanity. eMed

Linda Yaccarino

19,193 Aufrufe • vor 2 Monaten

There's a class of drugs called PCSK9 inhibitors that few people have heard of but Alex thinks will be far bigger than GLP-1s (which is already one of the best selling drugs of all time). They were discovered through a population born with a genetic mutation that gives them an 88% lifetime reduction in cardiovascular disease risk. The drugs mimic that mutation, significantly lowering our bad cholesterol and reducing the risk of a future heart attack or stroke. Alex describes them as close to a free lunch as there is in biology. "Because it is more asymmetric, it is more of a free lunch, I would argue that this medicine should be far bigger in terms of the number of people that are on it and the revenues associated with it than GLP-1s."

There's a class of drugs called PCSK9 inhibitors that few people have heard of but Alex thinks will be far bigger than GLP-1s (which is already one of the best selling drugs of all time). They were discovered through a population born with a genetic mutation that gives them an 88% lifetime reduction in cardiovascular disease risk. The drugs mimic that mutation, significantly lowering our bad cholesterol and reducing the risk of a future heart attack or stroke. Alex describes them as close to a free lunch as there is in biology. "Because it is more asymmetric, it is more of a free lunch, I would argue that this medicine should be far bigger in terms of the number of people that are on it and the revenues associated with it than GLP-1s."

Patrick OShaughnessy

223,532 Aufrufe • vor 4 Monaten

More than 1 billion people live with obesity worldwide — and the number is expected double by 2030. World Health Organization (WHO) has issued new recommendations on the use of GLP-1 medicines to treat obesity in adults. These medicines are powerful tools but no single drug can solve the obesity crisis. Obesity is a complex disease requiring comprehensive, lifelong care and action across many sectors. GLP-1s provide hope for millions around the world, and must be accessible to everyone who needs them equitably. Watch Tedros Adhanom Ghebreyesus ⬇️

More than 1 billion people live with obesity worldwide — and the number is expected double by 2030. World Health Organization (WHO) has issued new recommendations on the use of GLP-1 medicines to treat obesity in adults. These medicines are powerful tools but no single drug can solve the obesity crisis. Obesity is a complex disease requiring comprehensive, lifelong care and action across many sectors. GLP-1s provide hope for millions around the world, and must be accessible to everyone who needs them equitably. Watch Tedros Adhanom Ghebreyesus ⬇️

World Health Organization (WHO)

21,848 Aufrufe • vor 9 Monaten

Nestle says their company is looking to increase flavors in their products “to counter duller taste buds that can accompany GLP-1 weight loss drug” Nestle and the media is saying they will do things like “adding spices or more pepper” but that’s not at all what they really plan on doing I’ve made posts about this and what they are really doing is engineering foods to be more addictive to counter the GLP-1 drugs There's a food laboratory in Northern California called Mattson that is quote unquote creating the future of food. Mattson has conceptualized, developed, branded, and scaled hundreds of product lines, and in the process created billions of dollars in revenue for clients Right now their Big Food clients are asking them to do experiments that will reformulate ingredients so that their food can bypass the effects of Ozempic, wegovy and other GLP-1 weight loss drugs They’re engineering the food to be more addicting This is what I believe is really going on. Projects like this

Nestle says their company is looking to increase flavors in their products “to counter duller taste buds that can accompany GLP-1 weight loss drug” Nestle and the media is saying they will do things like “adding spices or more pepper” but that’s not at all what they really plan on doing I’ve made posts about this and what they are really doing is engineering foods to be more addictive to counter the GLP-1 drugs There's a food laboratory in Northern California called Mattson that is quote unquote creating the future of food. Mattson has conceptualized, developed, branded, and scaled hundreds of product lines, and in the process created billions of dollars in revenue for clients Right now their Big Food clients are asking them to do experiments that will reformulate ingredients so that their food can bypass the effects of Ozempic, wegovy and other GLP-1 weight loss drugs They’re engineering the food to be more addicting This is what I believe is really going on. Projects like this

Wall Street Apes

252,904 Aufrufe • vor 1 Monat

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

Metabolic Mind

20,561 Aufrufe • vor 1 Jahr

The next health revolution may come from individuals learning to control their own biology. In this conversation with a16z's Daisy Wolf, Andrew Huberman explores the remarkable ways emerging tools and cultural shifts are enabling people to optimize sleep, metabolism, focus, and performance. - How COVID accelerated a shift toward self-directed health and personal agency - Why resistance training, sunlight exposure, and sleep are the highest-leverage interventions for physical and cognitive performance - The transformative potential of GLP-1 drugs in treating obesity - Why peptides and emerging bio-optimization tools are gaining traction outside traditional medicine - The difference between reading biology (wearables, biomarkers) and writing to it ... and more. 0:00 Introduction 1:15 The health awakening, explained 7:02 MAHA's role in the health movement 13:05 GLP-1: Nearly one in seven Americans 18:37 The non-GLP peptide craze 25:16 Rogue experiments and low-dose GLP 31:40 Real-time cortisol sensing 44:39 The pet octopus and AI communication Andrew D. Huberman, Ph.D. Daisy Wolf

The next health revolution may come from individuals learning to control their own biology. In this conversation with a16z's Daisy Wolf, Andrew Huberman explores the remarkable ways emerging tools and cultural shifts are enabling people to optimize sleep, metabolism, focus, and performance. - How COVID accelerated a shift toward self-directed health and personal agency - Why resistance training, sunlight exposure, and sleep are the highest-leverage interventions for physical and cognitive performance - The transformative potential of GLP-1 drugs in treating obesity - Why peptides and emerging bio-optimization tools are gaining traction outside traditional medicine - The difference between reading biology (wearables, biomarkers) and writing to it ... and more. 0:00 Introduction 1:15 The health awakening, explained 7:02 MAHA's role in the health movement 13:05 GLP-1: Nearly one in seven Americans 18:37 The non-GLP peptide craze 25:16 Rogue experiments and low-dose GLP 31:40 Real-time cortisol sensing 44:39 The pet octopus and AI communication Andrew D. Huberman, Ph.D. Daisy Wolf

a16z

529,295 Aufrufe • vor 5 Monaten

Micro-dosing GLP-1 receptor agonists (drugs like semaglutide/Ozempic) could offer meaningful benefits while minimizing harmful side effects. There’s no doubt these drugs are incredibly effective for weight loss. But the high doses currently being used might be too much of a good thing. For example, high-dose GLP-1 receptor agonist use has been linked with a near doubling in the risk of suicidal behavior and a tripling in the risk of depression, as well as a two-fold increase in the risk of age-related macular degeneration. However, these drugs may still have utility when used strategically. According to Dr. Ben Bikman (Benjamin Bikman), micro-dosing GLP-1 receptor agonists intermittently may be a beneficial strategy to manage hunger, reset eating behaviors, and encourage healthier dietary patterns. Specifically, Bikman proposes that using low doses for about 90 days could fundamentally shift one's relationship with food. There is even some speculation that these medications may have pro-longevity benefits, independent of their effects on weight loss. To learn more, check out the new FMF episode with Dr. Ben Bikman. You can find it on YouTube, Spotify, and Apple Podcasts. Links in the comments.

Micro-dosing GLP-1 receptor agonists (drugs like semaglutide/Ozempic) could offer meaningful benefits while minimizing harmful side effects. There’s no doubt these drugs are incredibly effective for weight loss. But the high doses currently being used might be too much of a good thing. For example, high-dose GLP-1 receptor agonist use has been linked with a near doubling in the risk of suicidal behavior and a tripling in the risk of depression, as well as a two-fold increase in the risk of age-related macular degeneration. However, these drugs may still have utility when used strategically. According to Dr. Ben Bikman (Benjamin Bikman), micro-dosing GLP-1 receptor agonists intermittently may be a beneficial strategy to manage hunger, reset eating behaviors, and encourage healthier dietary patterns. Specifically, Bikman proposes that using low doses for about 90 days could fundamentally shift one's relationship with food. There is even some speculation that these medications may have pro-longevity benefits, independent of their effects on weight loss. To learn more, check out the new FMF episode with Dr. Ben Bikman. You can find it on YouTube, Spotify, and Apple Podcasts. Links in the comments.

Dr. Rhonda Patrick

47,689 Aufrufe • vor 1 Jahr

Andrew Huberman just broke down the next wave of weight-loss drugs on Gwyneth Paltrow’s goop podcast. He says the new triple agonist Retatrutide (currently in trials) is a big step up from Ozempic and Mounjaro. It hits three pathways (GLP-1 + glucagon + GIP) more gently, leading to significant weight loss with potentially less muscle loss and fewer side effects. People are already hunting for gray/black market versions. Early trial data on Retatrutide showed participants losing up to 24% of their body weight over 48 weeks, with notably better muscle preservation compared to earlier GLP-1 drugs when combined with resistance training. These next-generation drugs are becoming more targeted, but access, safety, and proper use remain key issues. This conversation made the rapid evolution of these drugs feel very real. It’s wild how fast this space is moving. What’s your take on the new generation of GLP drugs like Retatrutide?

Andrew Huberman just broke down the next wave of weight-loss drugs on Gwyneth Paltrow’s goop podcast. He says the new triple agonist Retatrutide (currently in trials) is a big step up from Ozempic and Mounjaro. It hits three pathways (GLP-1 + glucagon + GIP) more gently, leading to significant weight loss with potentially less muscle loss and fewer side effects. People are already hunting for gray/black market versions. Early trial data on Retatrutide showed participants losing up to 24% of their body weight over 48 weeks, with notably better muscle preservation compared to earlier GLP-1 drugs when combined with resistance training. These next-generation drugs are becoming more targeted, but access, safety, and proper use remain key issues. This conversation made the rapid evolution of these drugs feel very real. It’s wild how fast this space is moving. What’s your take on the new generation of GLP drugs like Retatrutide?

Camus

360,610 Aufrufe • vor 3 Monaten

This woman is saying what a lot of people need to hear. Her weight gain didn’t come out of nowhere. Mental health struggles, pouring everything into her job, and a broken relationship with food and movement all came first. She’s now treating her ADHD, working on her mindset around eating, and moving more consistently. GLP-1 meds might reduce her weight, but they don’t touch what’s really driving it: how she thinks, her mental health, and her relationship with food and herself. She’s not willing to risk her current stability just to make other people more comfortable with how she looks. The real fix isn’t just shrinking the body. It’s addressing what’s going on underneath. She’s pointing out that GLP-1s can change the weight but doesn't fix the mental and emotional stuff underneath. Do you agree with her?

This woman is saying what a lot of people need to hear. Her weight gain didn’t come out of nowhere. Mental health struggles, pouring everything into her job, and a broken relationship with food and movement all came first. She’s now treating her ADHD, working on her mindset around eating, and moving more consistently. GLP-1 meds might reduce her weight, but they don’t touch what’s really driving it: how she thinks, her mental health, and her relationship with food and herself. She’s not willing to risk her current stability just to make other people more comfortable with how she looks. The real fix isn’t just shrinking the body. It’s addressing what’s going on underneath. She’s pointing out that GLP-1s can change the weight but doesn't fix the mental and emotional stuff underneath. Do you agree with her?

End3of6Days9 (Helen) 🇺🇸

19,787 Aufrufe • vor 2 Monaten

New episode of HARD DRUGS! Should everyone be taking statins? Statins have revolutionised heart disease and they're one of many reasons for the long-term decline in cardiovascular mortality. Clinical trials suggest that the more you reduce LDL cholesterol levels, the more you reduce the risks of heart attacks and strokes, with no signal of harms even at the lowest levels. So scientists recommend the earlier they're taken the better, and the lower LDL levels you reach the better. Statins do have some rare side effects – such as muscle weakness and muscle loss in rare cases – but meta-analyses of RCTs find that most other side effects listed on statins' labels do not actually have higher risks than placebo. In this episode, Jacob Trefethen and I chat about all this and much more! - Why it took almost a century for scientists to come to consensus on "the lipid hypothesis": that higher levels of plasma LDL cholesterol causes higher risks of heart disease and that reducing it saves lives. - Drugs that effectively reduce cholesterol levels beyond the effect of statins, such as PCSK9 inhibitors, most of which are monoclonal antibodies, as well as newer siRNA drugs and the macrocyclic peptide enlicitide, which recently completed phase 3 trials, and Lp(a) drugs. - What the future holds for cholesterol drugs Timestamps: 0:00:00 Introduction 13:35 The decline in heart disease mortality 31:02 Surprising cholesterol trivia 55:40 The lipid hypothesis: 7 lines of evidence for the harms of LDL cholesterol 1:22:15 How cholesterol works 1:30:40 The discovery of statins 1:48:44 Should everyone be on statins? 1:57:10 PCSK9 drugs and beyond 2:22:56 Summary: how we got here and the future of cholesterol drugs Watch, listen, or read wherever you get your podcasts. Spotify: Apple: YouTube: Transcript:

New episode of HARD DRUGS! Should everyone be taking statins? Statins have revolutionised heart disease and they're one of many reasons for the long-term decline in cardiovascular mortality. Clinical trials suggest that the more you reduce LDL cholesterol levels, the more you reduce the risks of heart attacks and strokes, with no signal of harms even at the lowest levels. So scientists recommend the earlier they're taken the better, and the lower LDL levels you reach the better. Statins do have some rare side effects – such as muscle weakness and muscle loss in rare cases – but meta-analyses of RCTs find that most other side effects listed on statins' labels do not actually have higher risks than placebo. In this episode, Jacob Trefethen and I chat about all this and much more! - Why it took almost a century for scientists to come to consensus on "the lipid hypothesis": that higher levels of plasma LDL cholesterol causes higher risks of heart disease and that reducing it saves lives. - Drugs that effectively reduce cholesterol levels beyond the effect of statins, such as PCSK9 inhibitors, most of which are monoclonal antibodies, as well as newer siRNA drugs and the macrocyclic peptide enlicitide, which recently completed phase 3 trials, and Lp(a) drugs. - What the future holds for cholesterol drugs Timestamps: 0:00:00 Introduction 13:35 The decline in heart disease mortality 31:02 Surprising cholesterol trivia 55:40 The lipid hypothesis: 7 lines of evidence for the harms of LDL cholesterol 1:22:15 How cholesterol works 1:30:40 The discovery of statins 1:48:44 Should everyone be on statins? 1:57:10 PCSK9 drugs and beyond 2:22:56 Summary: how we got here and the future of cholesterol drugs Watch, listen, or read wherever you get your podcasts. Spotify: Apple: YouTube: Transcript:

Saloni

734,864 Aufrufe • vor 6 Monaten

It's surprisingly plausible that we got GLP-1 drugs because of Danish tax law. For tax reasons, Novo Nordisk is actually controlled by a non-profit foundation. There are many downsides of this. But one possible upside is that it's helped the company avoid institutional drift. The founding goals of the company were written into the non-profit's constitution, so now every new generation of leaders has to abide by them. In particular, the company is legally mandated to reinvest significant sums in R&D, regardless of the effect on shareholder value. That R&D gave us one of the major drug breakthroughs of this century so far.

It's surprisingly plausible that we got GLP-1 drugs because of Danish tax law. For tax reasons, Novo Nordisk is actually controlled by a non-profit foundation. There are many downsides of this. But one possible upside is that it's helped the company avoid institutional drift. The founding goals of the company were written into the non-profit's constitution, so now every new generation of leaders has to abide by them. In particular, the company is legally mandated to reinvest significant sums in R&D, regardless of the effect on shareholder value. That R&D gave us one of the major drug breakthroughs of this century so far.

Dwarkesh Patel

170,704 Aufrufe • vor 2 Monaten

Dr Oz says the Number 1 zip code in America using GLP-1’s is 10021, the Upper East side of Manhattan.. He goes on to say while it’s a temporary program now, they will monitor results for overall health benefits. These things in some cases paralyze your stomach from my understanding… and you body is never the same after that. What can go wrong?

Dr Oz says the Number 1 zip code in America using GLP-1’s is 10021, the Upper East side of Manhattan.. He goes on to say while it’s a temporary program now, they will monitor results for overall health benefits. These things in some cases paralyze your stomach from my understanding… and you body is never the same after that. What can go wrong?

MJTruthUltra

59,940 Aufrufe • vor 1 Monat

Dr. Paul Saladino: “One of the first issues I have with these GLPs is you’re probably on them FOR LIFE.” “So if Charles [Barkley] stops the GLP-1, the research is pretty clear that he’s going to regain the weight within one to two years…” PBD: “Why is that?” Dr. Saladino: “When you stop it, the eating habits that you never fixed will outpace the metabolism that’s been changed by the GLPs.” “These GLPs will slow down your metabolism because you’re eating less food. And so you’ve lost fat. You’ve also lost muscle mass. Muscle mass is positive for our metabolism. Muscle mass burns calories.” “There’s a study that came out saying that when you stop a GLP-1, you regain the weight four times faster than if you stopped exercise. Four times faster!”

Dr. Paul Saladino: “One of the first issues I have with these GLPs is you’re probably on them FOR LIFE.” “So if Charles [Barkley] stops the GLP-1, the research is pretty clear that he’s going to regain the weight within one to two years…” PBD: “Why is that?” Dr. Saladino: “When you stop it, the eating habits that you never fixed will outpace the metabolism that’s been changed by the GLPs.” “These GLPs will slow down your metabolism because you’re eating less food. And so you’ve lost fat. You’ve also lost muscle mass. Muscle mass is positive for our metabolism. Muscle mass burns calories.” “There’s a study that came out saying that when you stop a GLP-1, you regain the weight four times faster than if you stopped exercise. Four times faster!”

The Vigilant Fox 🦊

560,952 Aufrufe • vor 3 Monaten

#WATCH | Delhi: On GLP-1 Drugs, Dr Nikhil Tandon, Delhi AIIMS professor and HOD of Department of Endocrinology and Metabolism, says, “We can take many steps to reduce obesity. The first and foremost step towards it is physical activities and diet… The medicines which are used in weight control are always given with a foundation of diet control and physical activity. We have to make changes in our lifestyle first to achieve weight loss… After all this, if we are still not achieving the required weight, we should consult a doctor… Earlier, there were some medicines for weight loss which were withdrawn due to their side effects… A medicine is only approved when the benefits outweigh the risks, and it can reduce up to 5% of your weight. The GLP-1 was initially used for diabetic management but was later found to have an impact on weight… But one should not consume it recklessly as these are serious medicines for a serious problem… People should be careful as there can be side-effects…”

#WATCH | Delhi: On GLP-1 Drugs, Dr Nikhil Tandon, Delhi AIIMS professor and HOD of Department of Endocrinology and Metabolism, says, “We can take many steps to reduce obesity. The first and foremost step towards it is physical activities and diet… The medicines which are used in weight control are always given with a foundation of diet control and physical activity. We have to make changes in our lifestyle first to achieve weight loss… After all this, if we are still not achieving the required weight, we should consult a doctor… Earlier, there were some medicines for weight loss which were withdrawn due to their side effects… A medicine is only approved when the benefits outweigh the risks, and it can reduce up to 5% of your weight. The GLP-1 was initially used for diabetic management but was later found to have an impact on weight… But one should not consume it recklessly as these are serious medicines for a serious problem… People should be careful as there can be side-effects…”

ANI

23,146 Aufrufe • vor 5 Monaten

What's your goal... a number on the scale, or your health? Bariatric surgeon Dr. Bernie Hanna challenges one of the biggest mindset shifts people need to make during their weight loss journey. It's easy to get obsessed with a "goal weight," but he believes the real goal is something much bigger: feeling healthier, stronger, and happier in your own body. He also shares when GLP-1 medications can be part of that journey, along with the potential risks and why those risks are generally considered low. 🎙️ My conversation with Bernie Hanna MD is LIVE now on YouTube, Spotify, and Apple Podcasts. Comment “Health,” and we'll send you the full episode. Studio: Level 9 Studios Editor: AntMan Media

What's your goal... a number on the scale, or your health? Bariatric surgeon Dr. Bernie Hanna challenges one of the biggest mindset shifts people need to make during their weight loss journey. It's easy to get obsessed with a "goal weight," but he believes the real goal is something much bigger: feeling healthier, stronger, and happier in your own body. He also shares when GLP-1 medications can be part of that journey, along with the potential risks and why those risks are generally considered low. 🎙️ My conversation with Bernie Hanna MD is LIVE now on YouTube, Spotify, and Apple Podcasts. Comment “Health,” and we'll send you the full episode. Studio: Level 9 Studios Editor: AntMan Media

Ava Devines Bad Advice

13,811 Aufrufe • vor 1 Monat

Could GLP-1s impact aging and cognitive health? | Peter Attia, M.D. This clip is from episode # 370 of The Drive which was released on 10/27/25. In the full episode, I cover: -The state of evidence for alleged geroprotective effects of GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements -Risks and benefits associated with low-dose aspirin for cardiovascular disease (CVD) prevention -Evidence regarding optimal protein intake for maximizing muscle mass, and whether follistatin gene therapy might have promise for further increasing muscle gains -How to apply evidence-based reasoning to separate science from speculation in longevity research -More This AMA episode (Ep. # 370) is available exclusively for premium members. Become a member now to watch or listen on my website ( or your favorite podcast player.

Could GLP-1s impact aging and cognitive health? | Peter Attia, M.D. This clip is from episode # 370 of The Drive which was released on 10/27/25. In the full episode, I cover: -The state of evidence for alleged geroprotective effects of GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements -Risks and benefits associated with low-dose aspirin for cardiovascular disease (CVD) prevention -Evidence regarding optimal protein intake for maximizing muscle mass, and whether follistatin gene therapy might have promise for further increasing muscle gains -How to apply evidence-based reasoning to separate science from speculation in longevity research -More This AMA episode (Ep. # 370) is available exclusively for premium members. Become a member now to watch or listen on my website ( or your favorite podcast player.

Peter Attia

43,333 Aufrufe • vor 10 Monaten

$Bill Maher hits Huberman with a simple question: “What are peptides?” The answer unfolds into something much bigger. Peptides are short chains of amino acids our bodies produce naturally — insulin is one, GLP-1 is another. Now we’re synthesizing advanced versions like retatrutide, a triple agonist (GLP-1 + GIP + glucagon) that’s showing impressive results in trials, with substantial body weight reduction when combined with exercise. Huberman notes this could become a trillion-dollar drug for Eli Lilly, which is fiercely protecting its patent. Meanwhile, cheaper versions are circulating through compounding pharmacies and gray markets at a fraction of the cost and dose — creating a messy tension between big pharma exclusivity, FDA oversight, faster approval pathways, and real-world access. It reveals a deep split in how people view these tools: some trust only full pharma + FDA pipelines with extensive trials, while others see the pharma-FDA connection itself as a reason to seek alternatives. Peptides aren’t a standalone fix — lifestyle still matters hugely — but the discussion exposes the real friction: innovation needs investment, yet high prices and regulation push people toward less-controlled options with safety risks. What part of this landscape feels most unresolved to you — the breakthrough potential, the access vs. patent fight, or the growing trust divide?$

Bill Maher hits Huberman with a simple question: “What are peptides?” The answer unfolds into something much bigger. Peptides are short chains of amino acids our bodies produce naturally — insulin is one, GLP-1 is another. Now we’re synthesizing advanced versions like retatrutide, a triple agonist (GLP-1 + GIP + glucagon) that’s showing impressive results in trials, with substantial body weight reduction when combined with exercise. Huberman notes this could become a trillion-dollar drug for Eli Lilly, which is fiercely protecting its patent. Meanwhile, cheaper versions are circulating through compounding pharmacies and gray markets at a fraction of the cost and dose — creating a messy tension between big pharma exclusivity, FDA oversight, faster approval pathways, and real-world access. It reveals a deep split in how people view these tools: some trust only full pharma + FDA pipelines with extensive trials, while others see the pharma-FDA connection itself as a reason to seek alternatives. Peptides aren’t a standalone fix — lifestyle still matters hugely — but the discussion exposes the real friction: innovation needs investment, yet high prices and regulation push people toward less-controlled options with safety risks. What part of this landscape feels most unresolved to you — the breakthrough potential, the access vs. patent fight, or the growing trust divide?

Camus

452,262 Aufrufe • vor 4 Monaten

REPORT: 37% of Gen Z is planning on using Ozempic-like medications in 2025 to achieve their weight loss goals, according to a new report. When people say young Americans aren’t lazy, I point to reports like this. According to a survey from healthcare platform Tebra, 1 in 4 Americans, and 37% of Gen Z, are planning on turning to GLP-1 weight loss medications to lose weight. Instead of traditional methods like exercise and eating right, many Americans aren’t choosing to take the easier option. “Women plan to lose 23 pounds on average in 2025, while men are aiming for 19 pounds,” Tebra revealed. The number one reason people said they were turning to the medication was because they “want faster results.” Half of the people polled said they gave up their health goals in 2024 with 31% giving up by February. Source: tebra. com.

REPORT: 37% of Gen Z is planning on using Ozempic-like medications in 2025 to achieve their weight loss goals, according to a new report. When people say young Americans aren’t lazy, I point to reports like this. According to a survey from healthcare platform Tebra, 1 in 4 Americans, and 37% of Gen Z, are planning on turning to GLP-1 weight loss medications to lose weight. Instead of traditional methods like exercise and eating right, many Americans aren’t choosing to take the easier option. “Women plan to lose 23 pounds on average in 2025, while men are aiming for 19 pounds,” Tebra revealed. The number one reason people said they were turning to the medication was because they “want faster results.” Half of the people polled said they gave up their health goals in 2024 with 31% giving up by February. Source: tebra. com.

Collin Rugg

1,018,907 Aufrufe • vor 1 Jahr